{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T05:38:25Z","timestamp":1784785105883,"version":"3.55.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>CDK4\/6 inhibitors (CDKi), namely, palbociclib, ribociclib, and abemaciclib, combined with either an aromatase inhibitor (AI) or fulvestrant are the standard first\/second line for hormone receptor-positive(HR+)\/HER2-negative(neg) metastatic breast cancer (MBC). However, the choice of one specific CDKi is arbitrary and based on the physician\u2019s experience with the drug, toxicity profile, and patient\u2019s preferences, whereas biomarkers for optimal patient selection have not been established so far. Moreover, upfront chemotherapy is still recommended in case of clinical presentation with visceral crisis, despite no evidence of superior benefit for chemotherapy regimens against CDKi-based regimens. Recent correlative biomarker analyses from pivotal trials of palbociclib and ribociclib showed that HR+\/HER2-neg MBC might respond differently according to the molecular intrinsic subtype, with Luminal A and B tumors being sensitive to both CDKi, Basal-like being insensitive to endocrine therapy, irrespective of CDKi, and HER2-enriched tumors showing a benefit only with ribociclib-based therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical case<\/jats:title><jats:p>We hereby present a paradigmatic clinical case of a woman affected by a relapsed HR+\/HER2-neg MBC with bone and nodal lesions, presenting with a visceral crisis in the form of lymphangitis carcinomatosis and diagnosed with a molecularly HER2-enriched tumor, successfully treated with upfront ribociclib + fulvestrant. The patient experienced a complete symptomatic and radiologic remission of the lymphangitis with a partial response as best response, according to RECIST 1.1 criteria. The progression-free survival (PFS) was of 20 months, in line with the median PFS observed in the ribociclib + fulvestrant pivotal trial, where, however, patients with visceral crisis had been excluded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This clinical case confirms in the real-world setting that non-luminal subtypes can be found in HR+\/HER2-neg disease and may have potential therapeutic implications in the metastatic setting. It also questions the recommendation of upfront chemotherapy in the case of a visceral crisis in the era of CDKi-based regimens. These issues merit further evaluation in prospective and larger studies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.1009352","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T08:02:56Z","timestamp":1667894576000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive\/HER2-negative metastatic breast cancer with visceral crisis: A case report"],"prefix":"10.3389","volume":"12","author":[{"given":"Francesco","family":"Schettini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia","family":"Segu\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Sanfeliu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Gonzalez-Farre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Jares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergi","family":"Vidal-Sicart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergi","family":"Ganau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Cebrecos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fara","family":"Bras\u00f3-Maristany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleix","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,8]]},"reference":[{"key":"B1","unstructured":"NCCN guidelines for breast cancer, vers.42022"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01392","article-title":"Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update","volume":"39","author":"Burstein","year":"2021","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30804-6","article-title":"CDK4\/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US food and drug administration pooled analysis","volume":"21","author":"Gao","year":"2020","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa071","article-title":"Overall survival of CDK4\/6-inhibitors-based treatments in clinically relevant subgroups of metastatic breast cancer: systematic review and meta-analysis","volume":"112","author":"Schettini","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0305","article-title":"Overall survival with palbociclib and fulvestrant in women with HR+\/HER2- ABC: Updated exploratory analyses of PALOMA-3, a double-blind, phase III randomized study","volume":"28","author":"Cristofanilli","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"LBA1003","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1003","article-title":"Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor\u2013positive\/human epidermal growth factor receptor 2\u2013negative advanced breast cancer (ER+\/HER2\u2013 ABC): Analyses from PALOMA-2","volume":"40","author":"Finn","year":"2022","journal-title":"JCO"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/annonc\/annonc1089","article-title":"LBA15 - MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC)","volume":"33","author":"Goetz","year":"2022","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/annonc\/annonc894","article-title":"LBA4 - updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+\/HER2? advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL)","volume":"33","author":"Neven","year":"2022","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30420-6","article-title":"Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis","volume":"20","author":"Giuliano","year":"2019","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"233","DOI":"10.21037\/atm-21-5110","article-title":"Pharmacoeconomic evaluations of CDK4\/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review","volume":"10","author":"Zhu","year":"2022","journal-title":"Ann Transl Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.658747","article-title":"Cost-effectiveness analysis of abemaciclib plus fulvestrant in the second-line treatment of women with HR+\/HER2- advanced or metastatic breast cancer: A US payer perspective","volume":"8","author":"Wang","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1200\/JCO.20.02977","article-title":"Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA phase III studies","volume":"39","author":"Prat","year":"2021","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS21-GS2-00","article-title":"Abstract GS2-00: Correlative analysis of overall survival by intrinsic subtype across the MONALEESA-2, -3, and -7 studies of ribociclib + endocrine therapy in patients with HR+\/HER2\u2013 advanced breast cancer","volume":"82","author":"Carey","year":"2022","journal-title":"Cancer Res"},{"key":"B16","unstructured":"TruSight hereditary cancer panel | used with nextera flex for enrichment"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.1370","article-title":"Supervised risk predictor of breast cancer based on intrinsic subtypes","volume":"27","author":"Parker","year":"2009","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12920-015-0129-6","article-title":"Development and verification of the PAM50-based prosigna breast cancer gene signature assay","volume":"8","author":"Wallden","year":"2015","journal-title":"BMC Med Genomics"},{"key":"B20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41523-022-00451-9","article-title":"A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypes","volume":"8","author":"Schettini","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-2717","article-title":"Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer","volume":"77","author":"Cejalvo","year":"2017","journal-title":"Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ctrv.2018.04.015","article-title":"Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer","volume":"67","author":"Cejalvo","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.53347\/rID-1612","article-title":"Lymphangitic carcinomatosis | radiology reference article | radiopaedia.org","author":"Gaillard","year":"","journal-title":"Radiopaedia"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)\u2020","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2019.1595982","article-title":"Pulmonary lymphangitis carcinomatosis: systematic review and meta-analysis of case reports, 1970-2018","volume":"131","author":"Klimek","year":"2019","journal-title":"Postgrad Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1186\/s12885-018-4725-7","article-title":"Successfully treatment by eribulin in visceral crisis: a case of lymphangitic carcinomatosis from metastatic breast cancer","volume":"18","author":"Fumet","year":"2018","journal-title":"BMC Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-06001-w","article-title":"Cyclin-dependent kinase 4\/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment","volume":"186","author":"Raschi","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: highlights of the St gallen international expert consensus on the primary therapy of early breast cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41523-022-00448-4","article-title":"Impact of low versus negative estrogen\/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer","volume":"8","author":"Yoder","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41523-021-00308-7","article-title":"Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant\/adjuvant chemotherapy","volume":"7","author":"Dieci","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.2747","article-title":"Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype","volume":"25","author":"Rakha","year":"2007","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0751","article-title":"Biomarker analyses of response to cyclin-dependent kinase 4\/6 inhibition and endocrine therapy in women with treatment-na\u00efve metastatic breast cancer","volume":"26","author":"Finn","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00925","article-title":"Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer","volume":"37","author":"Turner","year":"2019","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00608","article-title":"CDK 4\/6 inhibitors as single agent in advanced solid tumors","volume":"8","author":"Schettini","year":"2018","journal-title":"Front Oncol"},{"key":"B36","unstructured":"A phase III, multicenter, open-label study of ribociclib vs. palbociclib in patients with advanced hormone receptor-positive\/HER2-negative\/HER2-Enriched breast cancer - HARMONIA trial2022"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2015.07.008","article-title":"Clinical implications of the intrinsic molecular subtypes of breast cancer","author":"Prat","year":"2015","journal-title":"Breast"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2021.07.019","article-title":"Dissecting the biological heterogeneity of HER2-positive breast cancer","volume":"59","author":"Schettini","year":"2021","journal-title":"Breast"},{"key":"B39","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41523-021-00351-4","article-title":"Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial","volume":"7","author":"Pascual","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1634\/theoncologist.2018-0407","article-title":"Everolimus plus exemestane for hormone receptor-positive advanced breast cancer: A PAM50 intrinsic subtype analysis of BOLERO-2","volume":"24","author":"Prat","year":"2019","journal-title":"Oncologist"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS21-P4-07-08","article-title":"Abstract P4-07-08: Prognostic value of intrinsic subtypes (IS) in hormone receptor-positive (HoR+) metastatic breast cancer (MBC): A systematic review and meta-analysis of prospective trials","volume":"82","author":"Schettini","year":"2022","journal-title":"Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.12.013","article-title":"Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL","volume":"32","author":"Martin","year":"2021","journal-title":"Ann Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4658-x","article-title":"First-line ribociclib plus letrozole in postmenopausal women with HR+, HER2\u2013 advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial","volume":"169","author":"Janni","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2019.08.009","article-title":"Progression-free survival outcome is independent of objective response in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with palbociclib plus letrozole compared with letrozole: Analysis from PALOMA-2","volume":"20","author":"Rugo","year":"2020","journal-title":"Clin Breast Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.1047","article-title":"Efficacy of CDK4\/6i in the visceral crisis setting: Result from a real-world database","volume":"39","author":"Dawood","year":"2021","journal-title":"J Clin Oncol"},{"key":"B47","first-page":"1057","article-title":"Chemotherapy dosing in the setting of liver dysfunction","volume":"19","author":"Eklund","year":"2005","journal-title":"Oncol (Williston Park)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1009352\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T08:03:00Z","timestamp":1667894580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1009352\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,8]]},"references-count":47,"alternative-id":["10.3389\/fonc.2022.1009352"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.1009352","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,8]]},"article-number":"1009352"}}